Molecular Mechanisms Underlying the Prevention of BCC Resistance
预防 BCC 耐药性的分子机制
基本信息
- 批准号:10330598
- 负责人:
- 金额:$ 36.45万
- 依托单位:
- 依托单位国家:美国
- 项目类别:
- 财政年份:2020
- 资助国家:美国
- 起止时间:2020-04-07 至 2025-01-31
- 项目状态:未结题
- 来源:
- 关键词:ATAC-seqAblationAffectAllelesAmericanAutomobile DrivingBasal Cell Nevus SyndromeBasal cell carcinomaBindingBiological AssayBiological ModelsBromodomainBypassCRISPR/Cas technologyCell ProliferationCell modelCellsChIP-seqChromatinChromatin Remodeling FactorCiliaClinicalClinical TrialsComplexDataDevelopmentDrug TargetingEpidermisEpigenetic ProcessErinaceidaeExhibitsFosteringGene Expression ProfileGeneticGerm-Line MutationGrowthHereditary DiseaseHistone AcetylationHumanImmunodeficient MouseImplantIn VitroIndividualLaboratoriesLifeLigand BindingMalignant Epithelial CellMalignant NeoplasmsModelingMolecularMusMutationNOD/SCID mouseNeoplasm MetastasisNucleosomesOncogenicOperative Surgical ProceduresOralPathogenesisPathway interactionsPatientsPharmaceutical PreparationsPharmacologyPharmacotherapyPhenotypePreclinical TestingPreventionProteinsProteomicsProto-OncogenesRecurrenceRegulationRepressionResistanceRoleSHH geneSafetySignal TransductionSucroseTestingTherapeutic IndexTumor BurdenTumor Suppressor Proteinsbasebench to bedsidechromatin modificationcombinatorialcostepigenomicsgenetic manipulationgenetic signaturegenome-wideimmunosuppressedimprovedin vivoin vivo evaluationinhibitorinsightkeratinocyteloss of functionmigrationmouse modelnoveloverexpressionpre-clinicalpreclinical efficacypreventpromoterreconstitutionrestorationside effectsmall molecule inhibitorsmoothened signaling pathwaytargeted treatmenttranscription factortranscriptome sequencingtranscriptomicstranslational approachtreatment strategytumortumor growthtumorigenicultraviolet irradiation
项目摘要
SUMMARY
BCCs are the most common type of human malignancy in the US, affecting more than 3 million Americans
annually. Defective regulation of Hedgehog (Hh) signaling, typically through loss of function of the tumor
suppressor Patched (PTCH) leading to oncogenic activation of SMO, are thought to be the primary drivers of
BCC growth. Ligand binding to PTCH relieves SMO repression, triggering its migration to the primary cilium with
activation of GLI transcription factors that drive cell proliferation/tumor growth. Aberrant HH signaling underlies
the Gorlin-Goltz syndrome, also known as basal cell nevus syndrome(BCNS), a dominantly inherited disorder in
which affected individuals are born with one functional PTCH allele and during life acquire mutations in the
second allele that accelerate HH signaling and drive the growth of BCCs in these patients whose inordinate
tumor burden necessitates multiple costly mutilating surgical procedures over their lifetime. Furthermore, Hh
inhibitors (HHi) are associated with intolerable side-effects in treated individuals such that half the patients
discontinue treatment despite substantial anti-tumor efficacy. Our group and others around the world have
fostered bench-to-bedside clinical trials with drugs that target HH signaling and in 2012 these efforts resulted in
FDA approval of vismodegib, a potent orally administered SMO inhibitor for the treatment of locally advanced,
surgically inoperable and potentially fatal BCCs. Despite their undeniable efficacy, the utility of currently available
HH signaling inhibitors is hampered by rapid development of tumor resistance and tumor recurrence. While
uninhibited Hh signaling clearly drives BCC resistance and recurrence, many BCCs do not manifest SMO
mutations indicating involvement of additional tumorigenic mechanisms. We have discovered that vismodegib
resistance involves dysregulation of the bromodomain-containing proteins BRD7 and BRD9 of the
SWItch/Sucrose NonFermentable (SWI/SNF) nucleosome remodeling complexes. Utilizing genetically well-
defined in vitro and in vivo murine models of BCC, and patient-derived human BCC cells, our preliminary data
compellingly demonstrate that (i) HHi resistance is associated with global decreases in histone acetylation and
chromatin accessibility, and (ii) genetic ablation of BRD7 renders drug-naïve BCC cells resistant to HHi. Based
on our preliminary data, this application will test the hypothesis that the BRD7-BRD9 nexus drives HHi resistance
and that the BRD9 blockade prevents the emergence of HHi resistance. Aim 1 will probe the chromatin
modifications and gene expression signatures associated with HHi resistance, and their relevance to the BRD7-
BRD9 axis. Aim 2 will test in vivo consequences of genetic manipulation of the BRD7 and BRD9 nexus in
genetically-defined models (i.e., epidermis-specific deletions in BRD7 [Brd7 KO] or Akt1 [Akt1+/-]. Aim 3 will test
the potential utility of select BRD9 and Akt inhibitors for overcoming/preventing HHi resistance using an in vivo
BCC model system developed in the PI’s laboratory that faithfully mimics human BCNS and previously was used
to verify the efficacy and safety of HHi.
概括
BCC 是美国最常见的人类恶性肿瘤,影响超过 300 万美国人
每年。 Hedgehog (Hh) 信号传导存在缺陷,通常是由于肿瘤功能丧失所致
抑制子补丁 (PTCH) 导致 SMO 致癌激活,被认为是 SMO 致癌的主要驱动因素
BCC 增长。配体与 PTCH 结合可缓解 SMO 抑制,从而触发其迁移至初级纤毛
激活驱动细胞增殖/肿瘤生长的 GLI 转录因子。异常 HH 信号传导的基础
Gorlin-Goltz 综合征,也称为基底细胞痣综合征 (BCNS),是一种显性遗传性疾病
受影响的个体出生时就带有一个功能性 PTCH 等位基因,并在一生中获得了 PTCH 等位基因突变
第二个等位基因加速 HH 信号传导并驱动这些患有异常疾病的患者的 BCC 生长
肿瘤负担使得在其一生中需要进行多次昂贵的残肢外科手术。此外,Hh
抑制剂(HHi)与接受治疗的个体中无法忍受的副作用相关,因此一半的患者
尽管具有显着的抗肿瘤功效,但仍停止治疗。我们的团队和世界各地的其他人已经
促进了针对 HH 信号传导的药物的从实验室到临床的临床试验,这些努力在 2012 年取得了成果
FDA 批准 vismodegib,一种有效的口服 SMO 抑制剂,用于治疗局部晚期、
无法手术且可能致命的 BCC。尽管它们具有不可否认的功效,但目前可用的实用性
HH 信号抑制剂受到肿瘤耐药性和肿瘤复发快速发展的阻碍。尽管
不受抑制的 Hh 信号明显导致 BCC 耐药和复发,许多 BCC 并不表现出 SMO
表明涉及其他致瘤机制的突变。我们发现 vismodegib
耐药性涉及含溴结构域蛋白 BRD7 和 BRD9 的失调。
SWIitch/蔗糖不可发酵 (SWI/SNF) 核小体重塑复合物。充分利用基因——
定义了 BCC 的体外和体内小鼠模型以及源自患者的人类 BCC 细胞,我们的初步数据
令人信服地证明 (i) HHi 抗性与组蛋白乙酰化的整体下降相关
染色质可及性,以及 (ii) BRD7 的基因消除使未接受过药物治疗的 BCC 细胞对 HHi 产生耐药性。基于
根据我们的初步数据,该应用程序将测试 BRD7-BRD9 连接驱动 HHi 抵抗的假设
并且 BRD9 阻断可以防止 HHi 耐药性的出现。目标 1 将探测染色质
与 HHi 抗性相关的修饰和基因表达特征及其与 BRD7-的相关性
BRD9 轴。目标 2 将测试 BRD7 和 BRD9 连接的基因操作的体内后果
基因定义的模型(即 BRD7 [Brd7 KO] 或 Akt1 [Akt1+/-] 中表皮特异性缺失。目标 3 将测试
选择 BRD9 和 Akt 抑制剂在体内克服/预防 HHi 耐药性的潜在效用
PI实验室开发的BCC模型系统,忠实模仿人类BCNS,之前曾使用过
验证HHi的有效性和安全性。
项目成果
期刊论文数量(0)
专著数量(0)
科研奖励数量(0)
会议论文数量(0)
专利数量(0)
数据更新时间:{{ journalArticles.updateTime }}
{{
item.title }}
{{ item.translation_title }}
- DOI:
{{ item.doi }} - 发表时间:
{{ item.publish_year }} - 期刊:
- 影响因子:{{ item.factor }}
- 作者:
{{ item.authors }} - 通讯作者:
{{ item.author }}
数据更新时间:{{ journalArticles.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ monograph.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ sciAawards.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ conferencePapers.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ patent.updateTime }}
DAVID RINSEY BICKERS其他文献
DAVID RINSEY BICKERS的其他文献
{{
item.title }}
{{ item.translation_title }}
- DOI:
{{ item.doi }} - 发表时间:
{{ item.publish_year }} - 期刊:
- 影响因子:{{ item.factor }}
- 作者:
{{ item.authors }} - 通讯作者:
{{ item.author }}
{{ truncateString('DAVID RINSEY BICKERS', 18)}}的其他基金
Tumor Immune Profiling to Optimize Clinical Trial Readiness in Basal Cell Nevus Syndrome
肿瘤免疫分析可优化基底细胞痣综合征的临床试验准备
- 批准号:
10046642 - 财政年份:2020
- 资助金额:
$ 36.45万 - 项目类别:
Molecular Mechanisms Underlying the Prevention of BCC Resistance
预防 BCC 耐药性的分子机制
- 批准号:
10552026 - 财政年份:2020
- 资助金额:
$ 36.45万 - 项目类别:
Molecular Mechanisms Underlying the Prevention of BCC Resistance
预防 BCC 耐药性的分子机制
- 批准号:
9974157 - 财政年份:2020
- 资助金额:
$ 36.45万 - 项目类别:
Tumor Immune Profiling to Optimize Clinical Trial Readiness in Basal Cell Nevus Syndrome
肿瘤免疫分析可优化基底细胞痣综合征的临床试验准备
- 批准号:
10221074 - 财政年份:2020
- 资助金额:
$ 36.45万 - 项目类别:
Columbia University Skin Disease Resource-Based Center (epiCURE)
哥伦比亚大学皮肤病资源中心 (epiCURE)
- 批准号:
9087989 - 财政年份:2016
- 资助金额:
$ 36.45万 - 项目类别:
Columbia University Skin Disease Resource-Based Center (epiCURE)
哥伦比亚大学皮肤病资源中心 (epiCURE)
- 批准号:
9765045 - 财政年份:2016
- 资助金额:
$ 36.45万 - 项目类别:
Non-melanoma skin cancer: A model for impact of aging on an environmental disease
非黑色素瘤皮肤癌:衰老对环境疾病影响的模型
- 批准号:
9204120 - 财政年份:2016
- 资助金额:
$ 36.45万 - 项目类别:
Mechanism-based abrogation of BCC pathogenesis
基于机制的 BCC 发病机制的消除
- 批准号:
8460080 - 财政年份:2012
- 资助金额:
$ 36.45万 - 项目类别:
Mechanism-based abrogation of BCC pathogenesis
基于机制的 BCC 发病机制的消除
- 批准号:
8610310 - 财政年份:2012
- 资助金额:
$ 36.45万 - 项目类别:
Mechanism-based abrogation of BCC pathogenesis
基于机制的 BCC 发病机制的消除
- 批准号:
8296459 - 财政年份:2012
- 资助金额:
$ 36.45万 - 项目类别:
相似海外基金
Targeted ablation of cerebral atherosclerosis using supramolecular self-assembly
利用超分子自组装靶向消融脑动脉粥样硬化
- 批准号:
24K21101 - 财政年份:2024
- 资助金额:
$ 36.45万 - 项目类别:
Grant-in-Aid for Early-Career Scientists
心房細動に対するPulsed Field Ablationの組織創傷治癒過程を明らかにする網羅的研究
阐明房颤脉冲场消融组织伤口愈合过程的综合研究
- 批准号:
24K11201 - 财政年份:2024
- 资助金额:
$ 36.45万 - 项目类别:
Grant-in-Aid for Scientific Research (C)
遅延造影心臓MRIによる心房細動Ablation冷却効果の比較:28 vs. 31 mm Cryoballoon
使用延迟对比增强心脏 MRI 比较房颤消融冷却效果:28 毫米与 31 毫米 Cryoballoon
- 批准号:
24K11281 - 财政年份:2024
- 资助金额:
$ 36.45万 - 项目类别:
Grant-in-Aid for Scientific Research (C)
InSPACE-VT_Development and Validation of Virtual Pace Mapping to Guide Catheter Ablation of Ventricular Tachycardia
InSPACE-VT_虚拟起搏测绘的开发和验证以指导室性心动过速导管消融
- 批准号:
EP/Z001145/1 - 财政年份:2024
- 资助金额:
$ 36.45万 - 项目类别:
Fellowship
CAREER: Heat Penetration Depth and Direction Control with Closed-Loop Device for Precision Ablation
职业:利用闭环装置控制热穿透深度和方向,实现精确烧蚀
- 批准号:
2338890 - 财政年份:2024
- 资助金额:
$ 36.45万 - 项目类别:
Continuing Grant
Collaborative Research: RUI: Frontal Ablation Processes on Lake-terminating Glaciers and their Role in Glacier Change
合作研究:RUI:湖终止冰川的锋面消融过程及其在冰川变化中的作用
- 批准号:
2334777 - 财政年份:2024
- 资助金额:
$ 36.45万 - 项目类别:
Continuing Grant
Collaborative Research: RUI: Frontal Ablation Processes on Lake-terminating Glaciers and their Role in Glacier Change
合作研究:RUI:湖终止冰川的锋面消融过程及其在冰川变化中的作用
- 批准号:
2334775 - 财政年份:2024
- 资助金额:
$ 36.45万 - 项目类别:
Continuing Grant
Collaborative Research: RUI: Frontal Ablation Processes on Lake-terminating Glaciers and their Role in Glacier Change
合作研究:RUI:湖终止冰川的锋面消融过程及其在冰川变化中的作用
- 批准号:
2334776 - 财政年份:2024
- 资助金额:
$ 36.45万 - 项目类别:
Continuing Grant
Cryo laser-ablation system (157+193nm) with 'triple-quad' plasma mass spectrometer, Cryo-LA-ICPMS/MS
带有“三重四极杆”等离子体质谱仪、Cryo-LA-ICPMS/MS 的冷冻激光烧蚀系统 (157 193nm)
- 批准号:
515081333 - 财政年份:2023
- 资助金额:
$ 36.45万 - 项目类别:
Major Research Instrumentation
MRI: Acquisition of a Laser Ablation - Inductively Coupled Plasma - Triple Quadrupole - Mass Spectrometer (LA-ICP-QQQ-MS) System For Research and Education
MRI:获取用于研究和教育的激光烧蚀 - 电感耦合等离子体 - 三重四极杆 - 质谱仪 (LA-ICP-MS/MS) 系统
- 批准号:
2320040 - 财政年份:2023
- 资助金额:
$ 36.45万 - 项目类别:
Standard Grant